34º Congresso Mineiro de Cardiologia
Acesse o site do congresso
1º Dia - 7/10/25
2º Dia - 7/11/25
3º Dia - 7/12/25

Aula SC 7C: Terapia endócrina no câncer de mama e próstata Voltar

Patrícia Tavares Felipe Marcati

Sessão científica 7: Cardio-oncologia - Frank Nunes e Themissa Helena Voss

Artigo Autor(es) Referência
Addressing Cardiovascular Risk of Prostate Cancer Hormonal Therapy. Ryan Charles J, Morgans Alicia K JACC. CardioOncology. 2020 Mar; 2(Mar):82-83. doi: 10.1016/j.jaccao.2020.02.002. pii: .
Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. Poon Darren M C, Tan Guang-Ming, Chan Kuen, Chan Marco T Y, Chan Tim-Wai, Kan Raymond W M, Lam Martin H C, Leung Clarence L H, Wong Kenneth C W, Kam Kevin K H, Ng Chi-Fai, Chiu Peter K F Frontiers in oncology. 2024 ; 14():1345322. doi: 10.3389/fonc.2024.1345322. pii: 1345322.
Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. Ng Choon Ta, Bonilla Hilda M Gonzalez, Bryce Alan H, Singh Parminder, Herrmann Joerg Current cardiology reports. 2023 Aug; 25(Aug):889-899. doi: 10.1007/s11886-023-01909-3. pii: .
Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer. Karantanos Theodoros, Karanika Styliani Annals of translational medicine. 2016 Mar; 4(Mar):99. doi: 10.21037/atm.2016.01.23. pii: 99.
Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis. Chan Jeffrey S K, Tang Pias, Hui Jeremy M Ho, Lee Yan H A, Dee Edward C, Ng Kenrick, Liu Kang, Tse Gary, Ng Chi Fai The Prostate. 2022 Nov; 82(Nov):1477-1480. doi: 10.1002/pros.24423. pii: .
Cardio-oncology in advanced prostate cancer. Chen Kenneth, Wong Ting Hong, Tan Yu Guang, Tay Kae Jack, Tan Wei Chong, Chan Johan, Ho Henry, Cheng Christopher, Teoh Jeremy Yuen-Chun, Chiu Peter Ka-Fung, Wang Hung Jen, Saad Marniza Binti, Kanesvaran Ravindran, Li You Quan, Ng Choon Ta, Tuan Jeffrey Kit Loong, Yuen John Shyi Peng Frontiers in oncology. 2024 ; 14():1386597. doi: 10.3389/fonc.2024.1386597. pii: 1386597.
Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Rillamas-Sun Eileen, Kwan Marilyn L, Iribarren Carlos, Cheng Richard, Neugebauer Romain, Rana Jamal S, Nguyen-Huynh Mai, Shi Zaixing, Laurent Cecile A, Lee Valerie S, Roh Janise M, Huang Yuhan, Shen Hanjie, Hershman Dawn L, Kushi Lawrence H, Greenlee Heather Breast cancer research and treatment. 2023 Aug; 201(Aug):117-126. doi: 10.1007/s10549-023-06997-x. pii: .
Endocrine therapies for breast and prostate cancers: Essentials for primary care. Chaput Genevieve, Sumar Nureen Canadian family physician Medecin de famille canadien. 2022 Apr; 68(Apr):271-276. doi: 10.46747/cfp.6804271. pii: .
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors. Huang Yuhan, Kwan Marilyn L, Heckbert Susan R, Smith Nicholas L, Othus Megan, Laurent Cecile A, Roh Janise M, Rillamas-Sun Eileen, Lee Valerie S, Kolevska Tatjana, Cheng Richard K, Irribarren Carlos, Nguyen-Huynh Mai, Hershman Dawn L, Kushi Lawrence H, Greenlee Heather Journal of the National Cancer Institute. 2025 Jul; 117(Jul):1401-1409. doi: 10.1093/jnci/djaf063. pii: .
Hormonal Therapy and Cardiovascular Health: Examining the Risk Among Premenopausal Women Diagnosed With Breast Cancer. Khosrow-Khavar Farzin, Azoulay Laurent JACC. CardioOncology. 2024 Dec; 6(Dec):919-921. doi: 10.1016/j.jaccao.2024.10.009. pii: .
Hormonal Therapy for Prostate Cancer. Desai Kunal, McManus Jeffrey M, Sharifi Nima Endocrine reviews. 2021 May; 42(May):354-373. doi: 10.1210/endrev/bnab002. pii: .
Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Okwuosa Tochi M, Morgans Alicia, Rhee June-Wha, Reding Kerryn W, Maliski Sally, Plana Juan-Carlos, Volgman Annabelle Santos, Moseley Kendall F, Porter Charles B, Ismail-Khan Roohi, Circulation. Genomic and precision medicine. 2021 Jun; 14(Jun):e000082. doi: 10.1161/HCG.0000000000000082. pii: .
Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study. Zeng Cheng, Li Hong, Wang Wenna, Li Lixi, Liu Binliang, Lan Bo, Li Qing, Yang Wenjing, Wang Jiani, Ma Fei Cardio-oncology (London, England). 2025 Apr; 11(Apr):35. doi: 10.1186/s40959-025-00333-6. pii: 35.
Prevalence of Preexisting Cardiovascular Diseases in Prostate Cancer Patients and Cardiac Risks of Hormonal Therapy. Alzahrani Abdullah Mousa, Al Shamsi Hend, Al Momen Mohammed, Al Fluij Abdullah, Al Matar Ashrafl Saudi journal of medicine & medical sciences. 2024 ; 12():60-64. doi: 10.4103/sjmms.sjmms_150_23. pii: .
Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study. Liu Jui-Ming, Lin Cheng-Chia, Chen Miao-Fen, Liu Kuan-Lin, Lin Cheng-Feng, Chen Tien-Hsing, Wu Chun-Te The Prostate. 2021 Feb; 81(Feb):194-201. doi: 10.1002/pros.24096. pii: .
Nenhuma revista foi definida para este congresso.